IL139211A0 - New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol - Google Patents

New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Info

Publication number
IL139211A0
IL139211A0 IL13921199A IL13921199A IL139211A0 IL 139211 A0 IL139211 A0 IL 139211A0 IL 13921199 A IL13921199 A IL 13921199A IL 13921199 A IL13921199 A IL 13921199A IL 139211 A0 IL139211 A0 IL 139211A0
Authority
IL
Israel
Prior art keywords
pindolol
reboxetine
disorders
new drug
drug combinations
Prior art date
Application number
IL13921199A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL139211A0 publication Critical patent/IL139211A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13921199A 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol IL139211A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8486098P 1998-05-08 1998-05-08
PCT/US1999/006523 WO1999058130A1 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Publications (1)

Publication Number Publication Date
IL139211A0 true IL139211A0 (en) 2001-11-25

Family

ID=22187677

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13921199A IL139211A0 (en) 1998-05-08 1999-04-14 New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol

Country Status (22)

Country Link
EP (1) EP1075264B1 (pt)
JP (1) JP2002514601A (pt)
KR (1) KR20010052319A (pt)
CN (1) CN1300217A (pt)
AT (1) ATE283694T1 (pt)
AU (1) AU764579B2 (pt)
BR (1) BR9909559A (pt)
CA (1) CA2326105A1 (pt)
DE (1) DE69922367T2 (pt)
EA (1) EA003469B1 (pt)
ES (1) ES2232128T3 (pt)
HU (1) HUP0101341A3 (pt)
IL (1) IL139211A0 (pt)
NO (1) NO20005621D0 (pt)
NZ (1) NZ508035A (pt)
PL (1) PL345351A1 (pt)
PT (1) PT1075264E (pt)
SI (1) SI1075264T1 (pt)
SK (1) SK14502000A3 (pt)
TR (1) TR200003262T2 (pt)
WO (1) WO1999058130A1 (pt)
ZA (1) ZA200005301B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286669B6 (sk) 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie
EP1459750B1 (en) * 1999-07-01 2005-06-01 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating fibromyalgia and other somatoform disorders
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
ATE376419T1 (de) 2002-12-27 2007-11-15 Otsuka Pharma Co Ltd Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
JP2012526832A (ja) * 2009-05-13 2012-11-01 スノビオン プハルマセウトイカルス インコーポレイテッド トランスノルセルトラリン及びセロトニン受容体1a作動剤/拮抗剤を含む組成物及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
AU6776196A (en) * 1995-08-16 1997-03-12 Eli Lilly And Company Potentiation of serotonin response

Also Published As

Publication number Publication date
PT1075264E (pt) 2005-01-31
SK14502000A3 (sk) 2001-05-10
EA003469B1 (ru) 2003-06-26
KR20010052319A (ko) 2001-06-25
CN1300217A (zh) 2001-06-20
NZ508035A (en) 2004-02-27
JP2002514601A (ja) 2002-05-21
AU764579B2 (en) 2003-08-21
ZA200005301B (en) 2001-10-01
BR9909559A (pt) 2000-12-19
EP1075264B1 (en) 2004-12-01
CA2326105A1 (en) 1999-11-18
HUP0101341A2 (hu) 2001-08-28
SI1075264T1 (en) 2005-06-30
DE69922367D1 (de) 2005-01-05
PL345351A1 (en) 2001-12-17
ATE283694T1 (de) 2004-12-15
TR200003262T2 (tr) 2001-03-21
HUP0101341A3 (en) 2006-07-28
WO1999058130A1 (en) 1999-11-18
DE69922367T2 (de) 2005-12-22
AU3546099A (en) 1999-11-29
ES2232128T3 (es) 2005-05-16
NO20005621L (no) 2000-11-07
NO20005621D0 (no) 2000-11-07
EP1075264A1 (en) 2001-02-14
EA200001162A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
RS20120158A3 (en) Phenyl-piperazine Derivatives As Serotonin Resorption Inhibitors
NO20064277L (no) 6-substituerte 2,3,4,5-tetrahydro-1H-benzo[d]azepiner som 5-HT2C reseptoragonister
EE200100441A (et) Monoamiinide taasomastamise inhibiitorid kesknärvisüsteemi haiguste raviks
DE60233655D1 (de) R und retinoid x rezeptorenmodulatoren
HK1089177A1 (en) Modulators of peripheral 5-ht receptors
NO20054913L (no) Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
IL139211A0 (en) New drug combinations of a n.a.r.i., preferably reboxetine, and pindolol
NO20070914L (no) Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander
ATE424825T1 (de) Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
MY136367A (en) Treatment of cognitive failure
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
WO2002040006A3 (en) Treatment of anxiety disorders
GEP20104888B (en) Use of carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
NO20085172L (no) 3-(1h-indol-3-yl)indan-1-ylaminderivater for behandlingen av depresjon og angst
HK1056120A1 (en) Use of quetiapine for attention deficit hyperactivity disorder or conduct disorder.
HUP0101748A2 (hu) Reboxetin alkalmazása idegrendszeri zavarok kezelésére szolgáló gyógyszerkészítmények előállítására
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
UA83017C2 (uk) Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
UA85198C2 (ru) Производные морфолина как ингибиторы повторного поглощения норэпинефрина
PT1282414E (pt) Compostos derivados de felbamato para o tratamento da dor neuropatica
PE20030364A1 (es) Sistemas de indan-1-ol varias veces sustituidos y procedimiento para su preparacion

Legal Events

Date Code Title Description
MM9K Patent not in force due to non-payment of renewal fees